Related by context. All words. (Click for frequent words.) 72 fallopian tube carcinoma 71 recurrent NSCLC 70 demonstrated antitumor activity 70 tumors GIST 70 erlotinib Tarceva ® 69 metastatic malignant 69 ThermoDox R 69 recurrent metastatic 69 dasatinib Sprycel ® 69 recurrent glioblastoma multiforme 69 metastatic pancreatic 68 papillary renal cell carcinoma 68 sorafenib Nexavar 68 essential thrombocythemia ET 68 ZACTIMA 68 unresectable tumors 68 evaluating tivozanib 68 Paraplatin ® 68 stage IIIb IV 67 cisplatin gemcitabine 67 LymphoStat B TM 67 lymphoid malignancies 67 monoclonal antibody conjugated 67 lexidronam injection 67 mitoxantrone plus 67 stage IIIB 67 Camptosar ® 67 metastatic gastric 67 imatinib Gleevec ® 67 anthracycline taxane 67 INSPIRE Trial Phase III 67 FUSILEV enhances 67 MAGE A3 ASCI 66 bladder ovarian 66 neoadjuvant treatment 66 humanised monoclonal antibody 66 Platinol ® 66 Peginterferon alfa 2b 66 Orally administered 66 metastatic bladder 66 metastatic renal 66 brivanib 66 AVASTIN 66 Tarceva TM 66 5 FU leucovorin 66 docetaxel Taxotere ® 66 bevacizumab Avastin R 66 metastatic colorectal 66 oropharyngeal candidiasis OPC 66 Doxil ® 66 cetuximab Erbitux ® 66 advanced metastatic renal 66 CYT# potent vascular disrupting 66 completely resected 66 refractory chronic lymphocytic 66 ® lenalidomide 66 novel emulsion formulation 66 refractory gastrointestinal stromal 66 relapsed MM 66 gastrointestinal stromal tumors GIST 66 Xeloda ® 66 Adjuvant Treatment 66 cutaneous T 66 Irinotecan 65 Phase #b/#a clinical 65 Hsp# Inhibitor 65 malignant ascites 65 adriamycin 65 pan histone deacetylase 65 basal cell carcinoma BCC 65 tamoxifen citrate 65 biliary tract cancer 65 SPRYCEL ® 65 thalidomide Thalomid 65 metastatic HER2 negative 65 orally administered inhibitor 65 beclomethasone dipropionate 65 docetaxel Taxotere 65 Panzem NCD 65 Achieves Primary Endpoint 65 receptor tyrosine kinase inhibitor 65 estramustine 65 Bosutinib 65 R sorafenib tablets 65 alkylating agent 65 LHRH receptor positive 65 liposomal formulation 65 gemcitabine carboplatin 65 leukemia AML 65 myelodysplastic myeloproliferative diseases 65 cetuximab Erbitux R 65 Amgen Neulasta R 65 chemotherapy FOLFOX 65 ThermoDox ® 65 metastatic GIST 65 Temsirolimus 65 Ixempra 65 evaluating picoplatin 65 CIMZIA TM certolizumab pegol 65 R lenalidomide 65 metastatic HER2 positive 65 Vicinium TM 65 nonmetastatic 65 Initiate Clinical Trial 65 forodesine 65 denileukin diftitox 65 gefitinib Iressa 65 Neulasta R 64 gemcitabine Gemzar 64 situ CIS 64 GW# [003] 64 sorafenib tablets 64 dacarbazine DTIC 64 novel histone deacetylase 64 Pemetrexed 64 trastuzumab Herceptin R 64 taxane chemotherapy 64 Selective Internal 64 Alkeran 64 Patients Treated With 64 Advanced Melanoma 64 cell lymphoma CTCL 64 systemic anaplastic large 64 SIR Spheres 64 Bazedoxifene 64 gemcitabine Gemzar ® 64 lung pancreatic 64 cisplatin chemotherapy 64 anthracyclines taxanes 64 advanced hepatocellular carcinoma 64 refractory colorectal cancer 64 Mitomycin C 64 MGd 64 Gemzar gemcitabine 64 assessing T DM1 64 skeletal metastases 64 beta 1a 64 docetaxel Taxotere R 64 taxane resistant 64 ixabepilone 64 breast pancreatic 64 Myelodysplastic Syndrome MDS 64 TO AVOID PREGNANCY WHILE 64 targeted antifolate 64 Aflibercept 64 pegylated liposomal doxorubicin 64 Fludara ® 64 metastatic hormone refractory 64 FASLODEX 64 relapsed refractory multiple myeloma 64 paclitaxel Taxol R 64 HER2 positive metastatic breast 64 Gemzar ® 64 oral deforolimus 64 Mitoxantrone 64 Leucovorin 64 liposomal doxorubicin 64 unresectable inoperable 64 Hormone Refractory Prostate Cancer 64 unresectable stage 64 Neoadjuvant 64 PI3K/Akt pathway inhibitor 64 carmustine 64 carcinoma HCC 64 Cutaneous T 64 cell carcinoma RCC 64 microsphere therapy 64 ovarian prostate 64 Combination REOLYSIN R 64 tiuxetan 64 BrachySil TM 64 IMA# 64 Stage IIB 64 PNP inhibitor 64 interferon gamma 1b 64 Albuferon TM 64 superficial basal cell carcinoma 64 Percutaneous vertebroplasty 64 hypoxia activated prodrug 64 Aplidin 64 CLL SLL 64 TNFerade TM 64 steroid refractory 64 refractory AML 64 sunitinib malate 64 Gliadel Wafer 63 VALSTAR TM 63 Initiates Phase II 63 concurrent chemoradiation 63 Temodar ® 63 toenail onychomycosis 63 targeted radiotherapeutic 63 5 fluorouracil leucovorin 63 oral prodrug 63 Bicalutamide 63 metastatic renal cell carcinoma 63 histologically confirmed 63 Cimzia TM 63 Bezielle 63 Phase 2b Clinical Trial 63 paclitaxel carboplatin 63 Neulasta ® 63 nilotinib Tasigna ® 63 neuroendocrine cancers 63 Archexin 63 colorectal liver metastases 63 vinorelbine tartrate 63 gemcitabine chemotherapy 63 commercialize deforolimus 63 histone deacetylase inhibitor 63 antibody MAb 63 Hodgkin lymphoma HL 63 histone deacetylase HDAC inhibitor 63 miconazole Lauriad ® 63 Capecitabine 63 dasatinib Sprycel 63 fallopian tube cancers 63 non squamous 63 gastric adenocarcinoma 63 Intravitreal 63 investigational oral inhibitor 63 chemotherapy cisplatin 63 Quinamed 63 novel oral anticoagulant 63 doublet chemotherapy 63 Vitrasert R 63 Xeloda capecitabine 63 Prolongs Survival 63 IMiDs ® 63 sunitinib Sutent 63 squamous non 63 Imatinib mesylate 63 etanercept Enbrel 63 Zarnestra 63 Rituxan rituximab 63 corticosteroid dexamethasone 63 opioid induced constipation OIC 63 reslizumab 63 FOLFOX6 chemotherapy regimen 63 Soft Tissue Sarcoma 63 non resectable metastatic 63 androgen receptor antagonist 63 mertansine 63 Completes Patient Enrollment 63 Platinol ® cisplatin 63 Initiates Enrollment 63 transarterial 63 oral beclomethasone dipropionate 63 Pharmacokinetics PK 63 adalimumab Humira 63 neoadjuvant setting 63 metastatic castration resistant 63 unresectable liver cancer 63 BCG refractory carcinoma 63 oncologic diseases 63 Glioblastoma Multiforme 63 KRAS mutations occur 63 accumulate preferentially 63 oral ridaforolimus 63 PD LID 63 refractory acute promyelocytic 63 TNF Tumor Necrosis Factor 63 BCG refractory 63 refractory cutaneous T 63 epirubicin cisplatin 63 treat chronic sinusitis 63 acyclovir Lauriad R 63 acetonide FA 63 acute myeloid 63 Zalypsis 63 bevacizumab Avastin ® 63 virus HCV protease inhibitor 63 castrate resistant prostate cancer 63 metastatic bone 63 Fluorouracil 63 superficial bladder cancer 63 Advanced Renal Cell 63 irinotecan doxorubicin oxaliplatin paclitaxel 63 refractory metastatic 63 antiangiogenic agent 63 Navelbine ® 63 RhuDex TM 63 Evoltra ® 63 locoregional recurrence 63 Shows Statistically Significant 63 Amgen Neulasta ® 63 TNFerade ™ 63 sorafenib Nexavar ® 63 unresectable 63 T1c 63 RANK Ligand inhibitor 63 intranasal formulation 63 standard chemotherapy regimen 63 5 Fluorouracil 63 Recurrent Chest Wall 63 PrevOnco 63 Surgical resection 63 ara C 63 KRN# 63 metastatic malignant melanoma 63 PKC# 63 recurrent malignant glioma 63 relapsed acute lymphoblastic 62 topically applied SEPA 62 2 methoxyestradiol 62 vapreotide acetate 62 p# MAP kinase inhibitor 62 pediatric acute lymphoblastic 62 hyperplasia BPH 62 drug zotarolimus 62 malignant pleural mesothelioma 62 hormone receptor negative 62 hepatocellular cancer 62 relapsed leukemia 62 FOLOTYN ® 62 advanced medullary thyroid 62 polycythemia vera PV 62 humanized therapeutic 62 nucleoside analog 62 gastrointestinal stromal 62 hepatocellular carcinoma HCC 62 paclitaxel poliglumex 62 neuropathy sparing 62 Refractory Hodgkin Lymphoma 62 Oxaliplatin 62 Relapsed Refractory 62 OncoVex 62 paclitaxel Taxol ® 62 chimeric monoclonal antibody 62 deep venous thromboses 62 Etoposide 62 MKC# MT 62 including eniluracil ADH 62 receiving highly emetogenic 62 mouse xenograft models 62 Nexavar ® 62 IL# PE#QQR 62 epithelial tumors 62 arsenic trioxide injection 62 alfa 2a 62 ErbB2 positive 62 Demonstrates Significant 62 panitumumab Vectibix 62 Afatinib 62 acute GvHD 62 irinotecan chemotherapy 62 Idiopathic Pulmonary Fibrosis 62 HERCEPTIN 62 IgG1 monoclonal antibody 62 subependymal giant cell 62 HBeAg + 62 Waldenstrom macroglobulinemia 62 Bayer HealthCare Onyx Pharmaceuticals 62 thetreatment 62 colorectal gastric 62 tyrosine kinase inhibitors TKIs 62 bortezomib Velcade R 62 HuMax 62 lymphomas leukemias 62 non splenectomized 62 Lenalidomide 62 Cloretazine 62 ® bortezomib 62 lenalidomide Revlimid R 62 relapsing multiple sclerosis 62 Metastatic Melanoma 62 radiation sensitizer 62 chronic idiopathic thrombocytopenic purpura 62 lintuzumab SGN 62 taxane chemotherapy administered 62 anti PlGF 62 chemoradiation therapy 62 Prednisone Against Refractory 62 tuberous sclerosis TS 62 Genasense ® 62 polycythemia vera essential thrombocythemia 62 CINTREDEKIN BESUDOTOX 62 Arimidex anastrozole 62 PEGylated interferon beta 1a 62 follicular Non Hodgkin 62 eribulin mesylate 62 AKT inhibitor 62 Kit CD# positive 62 radiation chemoradiation 62 immunotherapeutic vaccine 62 vinca alkaloids 62 pertuzumab 62 XL# XL# 62 Vidaza ® 62 Flu Cy 62 pancreatic prostate 62 induced macular edema 62 refractory indolent non 62 PEGylated anti 62 Opterone R 62 Amrubicin 62 Marqibo TM 62 epirubicin cyclophosphamide 62 BRAF mutant 62 relapsing remitting MS RRMS 62 Meets Primary Endpoint 62 Degarelix 62 Valopicitabine 62 hypereosinophilic syndrome 62 arthritis PsA 62 Nexavar sorafenib 62 Vascular Disrupting Agent 62 microtubule inhibitor 62 temozolomide Temodar 62 pancreatic NET 62 radiofrequency ablation RFA 62 HER2 positive metastatic 62 Angiotensin Converting Enzyme 62 paclitaxel Taxol 62 Chronic Myelogenous Leukemia CML 62 evaluating carfilzomib 62 transplantation HCT 62 investigational immunotherapy 62 malignant pleural mesothelioma MPM 62 Diffuse Large B 62 monoclonal antibody IgG1 Mab 62 pediatric Crohn disease 62 Initiates Clinical Trial 62 advanced unresectable 62 Solazed TM 62 sarcoma melanoma 62 relapsed ovarian cancer 62 Cetuximab Erbitux 62 OMNARIS HFA 62 metastatic RCC 62 Mycophenolate Mofetil 62 ALN HPN 62 Dapagliflozin 62 JAK2 inhibitor 62 prokinetic agent 62 Darinaparsin 62 depsipeptide 62 Annamycin 62 rheumatoid arthritis psoriatic arthritis 62 TLK# 62 Adjuvant chemotherapy 62 epithelial ovarian 62 iobenguane 62 cyclophosphamide methotrexate 62 unresectable Stage III 62 recurrent squamous cell carcinoma 62 radiotherapy RT 62 gemcitabine cisplatin 62 HMG CoA reductase inhibitors 62 irreversible inhibitor 62 Hycamtin ® 62 NASH Huntington 62 YONDELIS 62 prostate cancer mCRPC 62 sunitinib Sutent ® 62 fluoropyrimidine 62 chills fever headache 62 AAG geldanamycin analog 62 severe oral mucositis 62 Patients Treated 62 neratinib 62 Shows Promise Against 62 metastatic colorectal carcinoma 62 DCVax R 62 Gliadel R 62 taxane therapy 62 HDAC Inhibitor 62 Nitazoxanide 62 inhalation powder 62 Lubiprostone 62 previously untreated follicular 61 pan HDAC inhibitor 61 dextromethorphan quinidine 61 Tanespimycin 61 EGFR mutation positive 61 capecitabine Xeloda 61 colorectal ovarian 61 adjuvant radiotherapy 61 MELAS 61 plus gemcitabine 61 primary peritoneal 61 Convection Enhanced Delivery 61 Panzem ® 61 Allovectin 7 61 Kepivance 61 oral candidiasis 61 FOLFOX6 61 Mg Uk 61 Oral Mucositis 61 ZOLINZA 61 Vandetanib 61 Cotara ® 61 Receives Orphan Drug Designation 61 substantially excreted 61 pancreatic neuroendocrine 61 Arzerra ofatumumab 61 basiliximab 61 generation purine nucleoside 61 tamoxifen Nolvadex ® 61 catheter occlusion 61 Cell Lymphoma 61 Pegylated Interferon 61 topical gel formulation 61 rosiglitazone maleate 61 Severe Sepsis 61 proteasome inhibitor 61 INVANZ 61 TTF Therapy 61 Panzem R 61 Bevacizumab Avastin 61 tumor vascular disrupting 61 advanced HER2 positive 61 multi kinase inhibitor 61 darinaparsin ZIO 61 gemtuzumab ozogamicin 61 LHRH agonists 61 Proxinium TM 61 gastrointestinal stromal tumors 61 benign prostatic hypertrophy BPH 61 murine model 61 metastatic castrate resistant 61 EOquin TM 61 stage IIIB IV 61 ADP receptor antagonist 61 urothelial cancer 61 PEGINTRON TM 61 Erlotinib 61 Personalized Immunotherapy 61 Trial Evaluating 61 glioblastoma multiforme GBM 61 treat benign prostatic 61 platelet inhibitor 61 R Saizen R 61 pain palliation 61 hepatic metastases 61 DOXIL 61 novel VDA molecule 61 bendamustine 61 VEGFR2 inhibitor 61 mitogen activated ERK kinase 61 invasive ductal 61 pancreatic neuroendocrine tumors 61 secondary hyperparathyroidism 61 rALLy clinical trial 61 psoriasis rheumatoid arthritis 61 pouchitis 61 Squalamine 61 M2 subunit 61 hormone refractory metastatic prostate 61 Carcinoma 61 NMIBC 61 pancreatic adenocarcinoma 61 Study Evaluating 61 AA Amyloidosis 61 nonsmall cell lung cancer 61 Methylnaltrexone 61 haematologic malignancies 61 Fludarabine 61 MOVIPREP R 61 Pazopanib 61 patientswith 61 monoclonal anti 61 Vinorelbine 61 PANVAC VF 61 IMiDs ® compound 61 evaluating satraplatin 61 Diabetic Macular Edema DME 61 Zorbtive TM 61 orally inhaled 61 mycophenolate mofetil MMF 61 metastatic liver 61 Stage IIIB IV 61 Chronic lymphocytic leukemia 61 ORENCIA ® 61 huN# DM1 61 relapsed mantle 61 small molecule tyrosine 61 mRCC 61 SUPPRELIN R LA 61 Naive Patients 61 Anthracycline 61 Interferon beta 1a 61 pediatric malignancies 61 interferon beta 1a infertility 61 sapacitabine CYC# 61 Gemcitabine 61 small lymphocytic lymphoma 61 treatment naïve genotype 61 docetaxel cisplatin 61 antimetabolite 61 Diabetic Neuropathy 61 cediranib 61 topically administered 61 chemoradiotherapy 61 antiproliferative effects 61 gastrointestinal stromal tumor 61 refractory ovarian cancer 61 Newly Diagnosed Multiple Myeloma 61 rasagiline tablets 61 Daclizumab 61 Myelofibrosis 61 evaluating MGCD# [002] 61 hypervascular tumors 61 COPEGUS R 61 Investigational Treatment 61 esophageal gastric 61 CAELYX 61 efaproxiral 61 multicenter Phase III 61 kidney urologic 61 HGS ETR1 mapatumumab 61 Vidaza R 61 recurrent glioblastoma 61 RSR# 61 adjuvant cisplatin 61 myeloproliferative disorders 61 Elotuzumab 61 Gleevec Glivec 61 allogeneic hematopoietic stem cell 61 progesterone receptor negative 61 methylnaltrexone bromide 61 Phase IIb Trial 61 oral picoplatin 61 HepDirect prodrug 61 receiving prophylactic anticoagulation 61 Velcade bortezomib 61 refractory CLL 61 ritonavir boosted 61 refractory NSCLC 61 Ozarelix 61 OHR/AVR# 61 TRISENOX ® 61 Granted Orphan Drug 61 myeloid metaplasia 61 peritoneal carcinomatosis 61 Demonstrates Potential 61 humanized monoclonal 61 Presents Preclinical Data 61 volociximab 61 thromboembolisms 61 plasma kallikrein inhibitor 61 R abatacept 61 Ph + acute lymphoblastic 61 invasive lobular carcinoma 61 microwave hyperthermia 61 Improves Outcomes 61 aripiprazole Abilify 61 Toxicities 61 Retreatment 61 Neupogen ® 61 GVAX ® 61 metaglidasen 61 trabectedin 61 targets EpCAM expressing 61 metastatic carcinoma 61 HyperAcute 61 B Cell Lymphoma 61 Castration Resistant Prostate Cancer 61 squamous cell carcinoma SCC 61 vorinostat 61 Kamada AAT 61 basal cell skin 61 Zemplar Capsules 61 vinca alkaloid 61 Omacetaxine 61 resectable pancreatic cancer 61 Clolar ® 61 sodium thiosulfate STS 61 fibrosarcoma 61 induced mucositis 61 mapatumumab 61 reversible inhibitor 61 brain metastases originating 61 Vidaza azacitidine 61 immunoconjugate 61 Onalta ™ 61 Sudhir Agrawal D.Phil 61 IMiDs R 61 Liposomal 61 indinavir Crixivan 61 Gleevec resistant 61 Herceptin trastuzumab 61 Files IND 61 hematological diseases 61 cutaneous melanoma 61 resistant hormone refractory 61 post herpetic neuralgia PHN 61 DOXIL R 61 brand ciclesonide HFA 61 Levoleucovorin 61 unresectable locally advanced 61 resectable 61 trastuzumab DM1 61 non nucleoside inhibitor 60 ribavirin Copegus ® 60 PDX pralatrexate 60 Nilotinib 60 peripherally acting 60 Boniva ibandronate 60 KSP inhibitor 60 RhuDex ® 60 chronic thromboembolic pulmonary 60 systemic immunosuppressive drugs 60 cortisol synthesis 60 Previously Treated 60 Successfully Completes Phase 60 ovarian lung 60 somatostatin analog 60 Ridaforolimus 60 Pertuzumab 60 refractory chronic myeloid 60 temsirolimus Torisel 60 metformin XR 60 prostate carcinomas 60 hyaluronidase enzyme 60 FEMALES SHOULD BE ADVISED 60 Factor VIIa 60 Hervé Hoppenot President 60 liposome injection 60 vincristine doxorubicin 60 transitional cell carcinoma 60 exocrine pancreatic insufficiency EPI 60 axitinib 60 AVAPRO 60 oral anti arrhythmic 60 aspirin clopidogrel 60 DURIN TM 60 metastatic neuroendocrine tumors 60 Deforolimus 60 Apaziquone 60 fludarabine cyclophosphamide 60 Folfox 60 Antiviral Therapy 60 cinacalcet 60 noninfectious uveitis 60 Cytoxan ® 60 Complicated Skin 60 AstraZeneca Arimidex 60 5 FU capecitabine 60 Node Positive 60 miconazole Lauriad R 60 relapsed CLL 60 selective modulator 60 overactive bladder syndrome 60 interstitial pneumonitis 60 urothelial carcinoma 60 selective phosphodiesterase 60 ductal adenocarcinoma 60 mycosis fungoides 60 benign neoplasms 60 cromolyn sodium 60 Insegia 60 VNP#M 60 colorectal lung 60 Kinase Inhibitor 60 Acute myeloid leukemia 60 Celsion proprietary 60 anticancer compound 60 biologic antibody 60 investigational oral hepatitis C 60 Vitrasert ® 60 PrevOnco ™ 60 fosbretabulin 60 pegfilgrastim 60 relapsed Acute Myeloid 60 Adjuvant Chemotherapy 60 Melphalan 60 INS# [001] 60 lumiliximab 60 doxorubicin HCl liposome injection 60 Peginterferon 60 sirtuin inhibitor program 60 immunomodulatory therapy 60 carcinoid tumors 60 HBeAg negative 60 interstitial cystitis IC 60 flutamide 60 multicenter Phase II 60 CTAP# 60 recurrent GBM 60 unresectable HCC 60 PROVENGE ® 60 progressive metastatic prostate 60 pregabalin Lyrica 60 Pivotal Trial 60 parathyroid carcinoma 60 prostate carcinoma 60 fluorouracil leucovorin 60 Sutent sunitinib 60 LymphoStat B belimumab 60 localized renal 60 Philadelphia Chromosome Positive 60 TOCOSOL 60 trastuzumab Herceptin ® 60 eluting stent 60 Panzem R NCD 60 Wafer polifeprosan 60 abacavir Ziagen 60 oral chemotherapeutic agent 60 hyperphenylalaninemia HPA due 60 uremic pruritus 60 phase III isavuconazole 60 Sapacitabine 60 candidate XP# 60 vidofludimus 60 oral Hycamtin 60 Certolizumab pegol 60 cell lymphoma ALCL 60 Friedreich Ataxia FRDA 60 TAXOTERE R 60 HoFH 60 Previously Untreated 60 liposomal amphotericin B 60 Brentuximab Vedotin SGN 60 acyclovir Zovirax 60 Safinamide 60 Zemiva TM 60 histologic subtype 60 Interferon Beta 60 surgically resectable 60 Bronchiectasis 60 Efficacy Trial 60 EndoTAGTM 1 60 cetuximab Erbitux 60 antimitotic 60 Torisel temsirolimus 60 Non Alcoholic Steatohepatitis 60 Thal Dex 60 EGFR tyrosine kinase inhibitor 60 Copegus ribavirin 60 Phase IIb clinical trials 60 evaluating REVLIMID 60 dihydrochloride 60 Renal Cell Carcinoma RCC 60 Initiate Phase 60 haematological cancers 60 Solesta TM 60 PRN FDA Approves 60 Gleevec imatinib mesylate 60 vaginal candidiasis 60 ELACYT 60 BR.# 60 Phase 1b clinical trials 60 selective agonist 60 Pegylated interferon 60 Syncria R 60 doxorubicin cyclophosphamide 60 ibritumomab tiuxetan 60 Immunotherapeutic 60 #mg/#mg 60 metastatic adenocarcinoma 60 ARRY # 60 Single Dose 60 ZACTIMA TM ZD# 60 Enzastaurin 60 SinuNase TM 60 TNF Blockers 60 bleomycin 60 invasive lobular 60 debulking surgery 60 constipation OIC 60 CVac 60 transthyretin amyloidosis 60 PsA 60 Taxotere chemotherapy 60 Ibritumomab Tiuxetan 60 Multiple Myeloma MM 60 carboplatin paclitaxel 60 cytoreduction 60 Sanofi Aventis Taxotere 60 ATRA IV 60 castration resistant hormone refractory 60 docetaxel Injection Concentrate 60 Papillary 60 headache nasopharyngitis 60 xenograft models 60 Antitumor Activity 60 Percutaneous Transluminal Coronary Angioplasty 60 ACTEMRA TM 60 huC# DM4 60 Epratuzumab 60 Chronic Lymphocytic Leukemia CLL 60 TTR amyloidosis 60 Maribavir 60 Radiation Therapy SIRT 60 Tiuxetan 60 Virulizin ® 60 Anti VEGF 60 Unresectable 60 hPAM4 60 Tyrima 60 Squamous 60 Tykerb lapatinib 60 Presents Preclinical 60 xanthine oxidase inhibitor 60 Atypical Hemolytic Uremic Syndrome 60 Improves Survival 60 Patients Receiving 60 Traficet EN 60 e antigen HBeAg 60 ciprofloxacin hydrochloride 60 THALOMID ® 60 prostate cancer HRPC 60 candesartan cilexetil 60 severe hypersensitivity reactions 60 neoadjuvant 60 lymphoma CTCL 60 HCV NS5B polymerase 60 Taxotere docetaxel 60 RhuDex R 60 systemic fungal infections 60 phase IIb study 60 bladder carcinoma 60 pulmonary metastases 60 3 registrational trial 60 Tyrosine Kinase Inhibitors 60 hormone LHRH antagonist 60 taxane refractory 60 BRAF inhibitor 60 follicular lymphoma FL 60 adenomatous 60 randomized controlled Phase 60 Interferon Alfa 60 neovascular diseases 60 itraconazole Sporanox 60 squamous histology 60 Demonstrates Efficacy 60 Begins Dosing 60 hereditary emphysema 60 novel tubulin binding 60 included exfoliative dermatitis 60 Bosentan 60 primary hyperparathyroidism 60 paclitaxel cisplatin 60 mTOR inhibitor 60 differentiated thyroid 60 Roche Herceptin 60 Zolinza 60 multikinase inhibitor 60 TASKi3 60 immunomodulatory properties 60 Eculizumab 60 leukotriene receptor antagonist 60 Paraplatin ® carboplatin 60 Prospective Randomized 60 androgen independent 60 treatment naive genotype 60 Oropharyngeal Candidiasis 60 alpha interferons 60 malignant lymphomas 60 Squamous Cell 60 stage IIIA 60 radiolabeled TM# 60 developing Zerenex ferric 60 MetroGel 60 Hepatocellular Carcinoma 60 SUTENT ® 60 overactive bladder VANTAS R 60 xenograft model 60 cardiotoxic 60 Ribavirin causes 60 HER2 Positive 60 candidates Azedra TM 60 FOR FURTHER INFORMATION ABOUT 60 syngeneic 60 Mg Usa 60 relapsed refractory AML 60 refractory multiple myeloma 60 YONDELIS R 60 intraepithelial neoplasia 60 ALVESCO ® 60 cytokine refractory 60 intralesional 60 Liprotamase 60 palifermin 60 albumin bound paclitaxel 60 Phase #/#a trial 60 Adjunctive Therapy 60 Trobalt 60 advanced metastatic prostate 60 familial amyloidotic polyneuropathy FAP 60 atypical hemolytic uremic syndrome 60 recurrent glioblastoma multiforme GBM 60 targeted nucleotide prodrug 60 Pruvel TM 60 rituximab refractory 60 Investigational Oral 60 Pafuramidine 60 nasal decolonization 60 Bayer Nexavar 60 Multiple Ascending Dose 60 neoadjuvant chemotherapy 59 oblimersen 59 phase IIb trial 59 radiation enteritis 59 ® imatinib mesylate 59 KRAS mutant tumors 59 IV Busulfex 59 topical gel containing